TransCode Therapeutics, Inc. (RNAZ)
NASDAQ: RNAZ · Real-Time Price · USD
8.45
-0.07 (-0.82%)
At close: Apr 28, 2026, 4:00 PM EDT
8.40
-0.05 (-0.59%)
After-hours: Apr 28, 2026, 6:54 PM EDT
TransCode Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Selling, General & Admin | 5.77 | 5.95 | 7.15 | 8.4 | 3.4 | |
| Research & Development | 13.42 | 9.71 | 12.26 | 10.23 | 2.75 | |
| Operating Expenses | 19.19 | 15.66 | 19.42 | 18.63 | 6.15 | |
| Operating Income | -19.19 | -15.66 | -19.42 | -18.63 | -6.15 | |
| Interest Expense | -0.01 | -0.03 | -0.06 | -0.03 | -0.1 | |
| Interest & Investment Income | 0.08 | 0 | 0.01 | 0.02 | 0 | |
| Currency Exchange Gain (Loss) | -0.11 | -0.06 | - | - | - | |
| Other Non Operating Income (Expenses) | -8 | -1.01 | 0.92 | 1.08 | -0.59 | |
| EBT Excluding Unusual Items | -27.23 | -16.76 | -18.55 | -17.56 | -6.84 | |
| Merger & Restructuring Charges | -8.79 | - | - | - | - | |
| Gain (Loss) on Sale of Assets | - | 0 | - | - | -0 | |
| Other Unusual Items | 1.58 | - | - | - | - | |
| Pretax Income | -34.44 | -16.75 | -18.55 | -17.56 | -6.84 | |
| Income Tax Expense | 0.23 | - | - | - | - | |
| Net Income | -34.66 | -16.75 | -18.55 | -17.56 | -6.84 | |
| Preferred Dividends & Other Adjustments | 1.61 | 0.03 | - | - | - | |
| Net Income to Common | -36.27 | -16.79 | -18.55 | -17.56 | -6.84 | |
| Shares Outstanding (Basic) | 1 | 0 | - | - | - | |
| Shares Outstanding (Diluted) | 1 | 0 | - | - | - | |
| Shares Change (YoY) | 5392.22% | - | - | - | - | |
| EPS (Basic) | -52.59 | -1336.64 | - | - | - | |
| EPS (Diluted) | -52.59 | -1336.64 | - | - | - | |
| Free Cash Flow | -19.52 | -13.36 | -18.11 | -15.86 | -5.52 | |
| Free Cash Flow Per Share | -28.31 | -1063.68 | - | - | - | |
| EBITDA | -19.12 | -15.57 | -19.3 | -18.54 | -6.11 | |
| D&A For EBITDA | 0.08 | 0.09 | 0.12 | 0.1 | 0.04 | |
| EBIT | -19.19 | -15.66 | -19.42 | -18.63 | -6.15 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.